Covid-19 – Moderna vaccine shows nearly 95% protection.

Moderna says it is a "great day" and they plan to apply for approval to use the vaccine in the next few weeks.
covid-Vaccine-trials-US

Moderna announced that its Covid-19 vaccine was almost 95% effective, according to interim results, and it can be stored at standard refrigeration temperature.

The US biotech firm announced these positive results one week after the interim results of a vaccine developed by Pfizer and Germanpartner BioNTech showed 90% effectiveness in preventing symptomatic Covid-19 infection.

Moderna conducted its interim analysis based on the first 95 patients with Covid-19 infection and revealed that the vaccine had an efficacy of 94.5 per cent. The analysis showed 90 of those 95 Covid-19 patients had received the placebo, with the remaining five getting the vaccine.

“This has been incredible teamwork. I think none of us probably thought that we could get to this place in the last 10 months,” Stephane Bancel, the chief executive of Moderna, was quoted as saying.

Moderna stated that almost 42 per cent of participants were older or had other diseases like diabetes, obesity or high blood pressure. This group of people can be affected severely if they are infected with Covid-19.

Moderna’s vaccine is suitable for long-term storage and shipping, where it can be kept at minus 20 degrees Celsius for six months. It can also be kept at between two and eight degrees Celsius, which is standard refrigeration temperature, for 30 days.

This is different from Pfizer and BioNTech’s vaccine, which requires storage of between minus 70 and minus 80 degrees Celsius, from production until it can be used by patients.

So far, Moderna has included 30,000 volunteers in their Phase 3 trial. Its Covid-19 vaccine is expected to not be available outside the US until 2021.

Share:

Share on linkedin
Share on twitter
Share on facebook

More Posts

Send Us A Message